HRP20160949T1 - Novi sastavi i metode za liječenje karcinoma - Google Patents

Novi sastavi i metode za liječenje karcinoma

Info

Publication number
HRP20160949T1
HRP20160949T1 HRP20160949TT HRP20160949T HRP20160949T1 HR P20160949 T1 HRP20160949 T1 HR P20160949T1 HR P20160949T T HRP20160949T T HR P20160949TT HR P20160949 T HRP20160949 T HR P20160949T HR P20160949 T1 HRP20160949 T1 HR P20160949T1
Authority
HR
Croatia
Prior art keywords
methods
new compositions
carcinoma treatment
carcinoma
treatment
Prior art date
Application number
HRP20160949TT
Other languages
English (en)
Croatian (hr)
Inventor
Chiang Jia Li
Keith Mikule
Youzhi Li
Original Assignee
Boston Biomedical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical, Inc. filed Critical Boston Biomedical, Inc.
Publication of HRP20160949T1 publication Critical patent/HRP20160949T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
HRP20160949TT 2007-09-10 2008-09-10 Novi sastavi i metode za liječenje karcinoma HRP20160949T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97114407P 2007-09-10 2007-09-10
US1337207P 2007-12-13 2007-12-13
PCT/US2008/075906 WO2009036101A1 (en) 2007-09-10 2008-09-10 Novel compositions and methods for cancer treatment
EP08830633.7A EP2200431B1 (en) 2007-09-10 2008-09-10 Novel compositions and methods for cancer treatment

Publications (1)

Publication Number Publication Date
HRP20160949T1 true HRP20160949T1 (hr) 2016-10-07

Family

ID=40452461

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20160949TT HRP20160949T1 (hr) 2007-09-10 2008-09-10 Novi sastavi i metode za liječenje karcinoma
HRP20160625TT HRP20160625T1 (hr) 2007-09-10 2008-09-10 Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
HRP20160430TT HRP20160430T1 (hr) 2007-09-10 2008-09-10 Nova grupa inhibitora stat3 puta i inhibitora puta matičnih stanica karcinoma

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20160625TT HRP20160625T1 (hr) 2007-09-10 2008-09-10 Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
HRP20160430TT HRP20160430T1 (hr) 2007-09-10 2008-09-10 Nova grupa inhibitora stat3 puta i inhibitora puta matičnih stanica karcinoma

Country Status (14)

Country Link
US (12) US8877803B2 (enExample)
EP (6) EP3067054B1 (enExample)
JP (16) JP5688840B2 (enExample)
CN (6) CN101854930B (enExample)
CA (4) CA2736563C (enExample)
CY (3) CY1117604T1 (enExample)
DK (4) DK2194987T3 (enExample)
ES (3) ES2584904T3 (enExample)
HR (3) HRP20160949T1 (enExample)
HU (3) HUE029111T2 (enExample)
PL (4) PL2190429T3 (enExample)
PT (2) PT2194987T (enExample)
SI (3) SI2190429T1 (enExample)
WO (3) WO2009036059A2 (enExample)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1848414T3 (pl) 2005-02-03 2011-10-31 Wyeth Llc Sposób leczenia nowotworu opornego na gefitinib
WO2007056118A1 (en) 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
CA2736563C (en) * 2007-09-10 2016-01-26 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20130331294A1 (en) 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
NZ590372A (en) 2008-07-08 2012-09-28 Univ Texas Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats)
SMT201700084T1 (it) 2008-08-04 2017-03-08 Wyeth Llc Associazioni antineoplastiche di 4-anilino-3-cianochinoline e capecitabina
AU2009322625A1 (en) 2008-12-01 2011-07-21 University Of Central Florida Research Foundation, Inc. Drug composition cytotoxic for pancreatic cancer cells
HUE061640T2 (hu) 2009-04-06 2023-07-28 Wyeth Llc Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával
CN101897979B (zh) * 2009-05-27 2012-08-22 上海市计划生育科学研究所 治疗前列腺疾病的靶向药物
WO2011069141A2 (en) 2009-12-04 2011-06-09 Board Of Regents, The University Of Texas System Interferon therapies in combination with blockade of stat3 activation
JP5794922B2 (ja) * 2009-12-28 2015-10-14 一般社団法人ファルマバレープロジェクト支援機構 １，３，４−オキサジアゾール−２−カルボキサミド化合物
US20110275577A1 (en) * 2010-01-08 2011-11-10 Moleculin, Llc Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
EP2542155B1 (en) 2010-03-01 2015-11-04 TAU Therapeutics LLC Method for imaging a disease
LT2547205T (lt) 2010-03-19 2024-06-10 1Globe Biomedical Co., Ltd. Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai
AU2015218436B9 (en) * 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
EP3108750B1 (en) * 2010-03-19 2018-07-04 1Globe Biomedical Co., Ltd. Novel compounds and compositions for targeting cancer stem cells
MX394137B (es) 2010-03-19 2025-03-24 Boston Biomedical Inc Compuestos y composiciones novedosas para atacar las células madre del cáncer.
WO2011130677A1 (en) * 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of cancer stem cells
US20110301194A1 (en) * 2010-06-02 2011-12-08 Arqule, Inc. Method for Determining Treatment Efficacy
CN103153975B (zh) * 2010-08-24 2016-01-20 杭州益尔生物科技有限公司 用于疾病治疗的新型萘醌
EP2617435A4 (en) * 2010-09-16 2014-03-12 Univ Osaka THERAPEUTICS AND PROPHYLACTIC AGENTS FOR COMPOSITIONS OF AUTOIMMUNE DISEASES, INFLAMMATORY DISEASES, ALLERGIC DISEASES AND ORGAN TRANSPLANTS
EP2643001A4 (en) * 2010-11-22 2014-02-19 Glaxosmithkline Ip Dev Ltd METHOD OF TREATING CANCER
WO2012071648A1 (en) * 2010-11-30 2012-06-07 London Health Sciences Centre Research Inc. Egfr antagonist for the treatment of heart disease
WO2012078982A2 (en) * 2010-12-09 2012-06-14 The Ohio State University Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
CN103402993A (zh) * 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
EP3251671A1 (en) * 2011-06-06 2017-12-06 Akebia Therapeutics Inc. Compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
SG10201601917XA (en) * 2011-09-12 2016-04-28 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
EP2776586B1 (en) * 2011-11-11 2018-03-07 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
JP2015506990A (ja) * 2012-02-17 2015-03-05 ゾウシャン ハイジョンジョウ シンシェン ファーマシューティカルズ カンパニー リミテッドＺｈｏｕｓｈａｎ Ｈａｉｚｈｏｎｇｚｈｏｕ Ｘｉｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． ４，９−ジヒドロキシ−ナフト［２，３−ｂ］フラン脂肪族酸エステルの誘導体の水性ナノ粒子懸濁液を調製する方法
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
SG10201805807PA (en) 2012-06-26 2018-08-30 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN106421795A (zh) * 2012-10-08 2017-02-22 贾力 预防原发性肿瘤在手术切除后再转移的药用组合物
DE102013003107A1 (de) 2013-02-25 2014-09-11 Thomas Rühl Naphthofurandione mit einer 1-Bromalkylgruppe oder einer 1-Hydroxyalkylgruppe in 2-Position und einer Alkylgruppe in 3-Position zum Furanring-Sauerstoff und Verfahren zu deren Herstellung
CN105492011A (zh) 2013-04-08 2016-04-13 丹尼斯·M·布朗 不理想给药化学化合物的治疗增效
MX2015014181A (es) * 2013-04-09 2016-05-24 Boston Biomedical Inc 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
EP2992018B1 (en) 2013-04-29 2019-02-13 OGD2 Pharma Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer
US10745489B2 (en) 2013-04-29 2020-08-18 Ogd2 Pharma Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PH12016500582B1 (en) 2013-10-04 2023-06-30 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
RU2016128396A (ru) * 2014-01-27 2018-03-02 Бостон Биомедикал, Инк. Новые способы лечения рака
EP3102036A4 (en) * 2014-02-07 2017-09-20 Boston Biomedical, Inc. 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof
US11406707B2 (en) 2014-02-10 2022-08-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 phosphorylation during graft-versus-host disease
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
JP6894236B2 (ja) * 2014-03-26 2021-06-30 デノボ バイオファーマ エルエルシー 免疫刺激活性を有するレトロウイルスベクター
WO2015164870A1 (en) 2014-04-25 2015-10-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gamma-aa-peptide stat3/dna inhibitors and methods of use
WO2015171985A1 (en) * 2014-05-09 2015-11-12 The Brigham And Women's Hospital, Inc. Treatment of igg-immune complex-mediated organ damage
ES2792851T3 (es) * 2014-06-09 2020-11-12 Kyoto Pharma Ind Derivados de naftofurano para uso como agentes antineoplásicos
US10869926B2 (en) * 2014-07-15 2020-12-22 The Johns Hopkins University Suppression of myeloid derived suppressor cells and immune checkpoint blockade
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
US10906914B2 (en) 2015-01-08 2021-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Furoquinolinediones as inhibitors of TDP2
JP6630364B2 (ja) 2015-03-27 2020-01-15 ボストン バイオメディカル， インコーポレイテッド 水溶性プロドラッグ
CN104725480A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 一种信号传导及转录激活因子抑制多肽及其应用
CN104693279A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 关于信号传导及转录激活因子抑制多肽及其应用
CN104693280A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 信号传导及转录激活因子抑制多肽及其应用
BR112017022281A2 (pt) * 2015-04-17 2018-07-10 Boston Biomedical Inc métodos para tratar câncer
TW201713328A (zh) * 2015-04-17 2017-04-16 波士頓生醫公司 治療癌症之方法
MX2017013358A (es) * 2015-04-17 2018-08-01 Boston Biomedical Inc Métodos para tratar el cáncer.
BR112017022958A2 (pt) * 2015-04-27 2018-07-17 Boston Biomedical Inc métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase
RS57371B1 (sr) * 2015-05-14 2018-08-31 NuCana plc Tretman kancera
EP3294299A1 (en) * 2015-05-15 2018-03-21 Novartis AG Methods for treating egfr mutant cancers
WO2016196935A1 (en) * 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
US10329267B2 (en) 2015-07-17 2019-06-25 Sumitomo Dainippon Pharma Co., Ltd. Method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017023866A1 (en) * 2015-07-31 2017-02-09 Boston Biomedical, Inc. Method of targeting stat3 and other non-druggable proteins
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
US20190017054A1 (en) * 2016-01-07 2019-01-17 Luni Emdad Method of modulating survival and stemness of cancer stem cells by mda-9/syntenin (sdcbp)
WO2017132049A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
CN109104862A (zh) * 2016-03-01 2018-12-28 中央研究院 4,9-二氧代-4,9-二氢萘并[2,3-b]呋喃-3-羧酰胺衍生物及其用于治疗增生性疾病与感染性疾病的用途
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017164379A1 (ja) * 2016-03-25 2017-09-28 大日本住友製薬株式会社 ２－アルキルカルボニルナフト［２，３－ｂ］フラン－４，９－ジオンの関連物質の製造方法、及びその関連物質
JP2017171640A (ja) * 2016-03-25 2017-09-28 学校法人兵庫医科大学 癌の治療システム
CN105837541A (zh) * 2016-04-23 2016-08-10 何淑琼 磷酸苯丙哌林的药物组合物及其在生物医药中的应用
CN105906595A (zh) * 2016-04-23 2016-08-31 陈斌 丙酸倍氯米松的药物组合物及其在生物医药中的应用
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018005444A2 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
CN106380456B (zh) * 2016-08-29 2019-03-26 中南大学 一种合成苯并呋喃萘醌衍生物的方法
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US20190375723A1 (en) 2016-11-22 2019-12-12 Boston Biomedical, Inc. New Naphtho[2,3-B]Furan Derivatives
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
EP3548086A1 (en) * 2016-11-30 2019-10-09 Tyme, Inc. Tyrosine derivatives and compositions comprising them
US20190358212A1 (en) * 2017-01-22 2019-11-28 Jiangsu Hengrui Medicine Co., Ltd. Uses of egfr/her2 inhibitor combined with pyrimidine-type anti-metabolic drug
WO2018183908A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer
EP3635410A4 (en) * 2017-06-04 2021-03-10 Rappaport Family Institute for Research in the Medical Sciences PROCEDURE FOR PREDICTING PERSONALIZED RESPONSE TO CANCER TREATMENT USING IMMUNE CHECKPOINT INHIBITORS AND KITS
JP7387177B2 (ja) * 2017-07-20 2023-11-28 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ パルス磁場勾配を使用する悪性癌細胞の標的化浸透圧溶解
CA3074981A1 (en) 2017-09-22 2019-03-28 Sumitomo Dainippon Pharma Co., Ltd. Chemically activated water-soluble prodrug
IL274698B2 (en) * 2017-11-16 2025-04-01 Tyrnovo Ltd Combinations of IRS/STAT3 activity modulators and PD–1/PD–L1 antibodies for cancer treatment
EP3501511A1 (en) * 2017-12-22 2019-06-26 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Means for preventing and treating brain metastasis
WO2019131940A1 (ja) * 2017-12-28 2019-07-04 株式会社カネカ 多能性幹細胞凝集抑制剤
CN107973788B (zh) * 2018-01-09 2021-07-09 沈阳药科大学 Bbi608衍生物及其制备与用途
BR112020017481A8 (pt) 2018-03-20 2022-12-06 Sumitomo Dainippon Pharma Co Ltd Derivados de di-hidrocromeno
DK3773537T3 (en) * 2018-04-19 2022-04-25 Tvardi Therapeutics Inc Stat3-hæmmere
WO2019232214A1 (en) 2018-05-31 2019-12-05 Boston Biomedical, Inc. Methods of using napabucasin
CN112703001A (zh) * 2018-09-18 2021-04-23 株式会社益力多本社 使用喹啉羧酰胺衍生物的癌症联用疗法
CN120168498A (zh) * 2018-10-12 2025-06-20 北京强新生物科技有限公司 治疗化疗难治性癌症的新联合用药方案
CN109223758A (zh) * 2018-10-31 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴类stat3抑制剂联合用药物组合物
CN109966297A (zh) * 2018-10-31 2019-07-05 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂马来酸盐晶型i联合用药物组合物
CN109846888A (zh) * 2018-10-31 2019-06-07 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和吲哚类stat3抑制剂联合用药物组合物
CN109288846A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat3抑制剂晶型a联合用药物组合物
CN109288845A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种咔唑类stat抑制剂马来酸盐晶型ii联合用药物组合物及其制备方法
CN109288847A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂甲磺酸盐晶型p联合用药物组合物
CN109172563A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种噻吨酮类紫杉醇和stat3抑制剂联合用药物组合物
CN109200052A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴酮类stat3抑制剂联合用药物组合物
CN109200044A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂酒石酸盐联合用药物组合物
CN109331004A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂甲磺酸盐A晶型联合用药物组合物
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
CN111374981B (zh) * 2019-04-09 2023-09-26 健艾仕生物医药有限公司 匹莫齐特和甲氨蝶呤的药物组合及其应用
US11564913B2 (en) 2019-05-03 2023-01-31 Children's Hospital Medical Center Compositions and methods for treating cancer
CN110218198B (zh) * 2019-05-22 2022-06-28 广州中医药大学(广州中医药研究院) 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用
JPWO2020251015A1 (enExample) * 2019-06-14 2020-12-17
JP7287929B2 (ja) * 2019-09-25 2023-06-06 住友ファーマ株式会社 ジヒドロクロメン誘導体を含有する医薬
WO2021089791A1 (en) * 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021101902A1 (en) * 2019-11-20 2021-05-27 Yale University Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
CN115297850A (zh) * 2019-12-05 2022-11-04 得克萨斯州大学系统董事会 用于肝纤维化和其他与纤维化相关的疾病的基于外排体的治疗
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021185234A1 (zh) * 2020-03-16 2021-09-23 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
WO2021230956A1 (en) * 2020-05-11 2021-11-18 Purdue Research Foundation Scaled-up synthesis of lomustine under continuous flow conditions
CN114286684B (zh) * 2020-07-27 2024-01-05 华中科技大学 与stat3相关的疾病的预防和/或治疗
WO2022216930A1 (en) * 2021-04-08 2022-10-13 Virginia Commonwealth University Novel mda-9 antagonist with anti-metastatic potential
CN114591306B (zh) * 2022-03-03 2024-03-01 陕西中医药大学 一种1,2,4-三唑环的1,4萘醌类stat3抑制剂及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472133A (en) * 1947-03-20 1949-06-07 Du Pont Thiophanthraquinone derivatives
SU1049490A1 (ru) 1982-05-18 1983-10-23 Ордена Трудового Красного Знамени Институт Химии Ан Мсср (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции
JPS616149A (ja) 1984-06-20 1986-01-11 Mitsubishi Electric Corp 無機絶縁体の製法
JPS63196576A (ja) * 1987-02-10 1988-08-15 Tetsuo Ikegawa フラルナフトキノン誘導体と制癌剤及びその製造方法
EP0309926A3 (de) 1987-09-29 1990-12-05 Siemens Aktiengesellschaft Verfahren zur Herstellung vollparametrisierbarer Schaltungen in integrierter Schaltkreistechnik
JPH01121284A (ja) 1987-11-06 1989-05-12 Eisai Co Ltd トコフェロール　ｎ，ｎ−ジアルキルアミノアルキルカルボン酸エステルの胆汁酸塩
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
JP2942015B2 (ja) * 1990-07-10 1999-08-30 キヤノン株式会社 電子写真感光体およびそれを用いた電子写真装置
DE69131874T2 (de) * 1990-07-10 2000-06-15 Canon K.K., Tokio/Tokyo Elektrophotographisches empfindliches Element
TW252136B (enExample) 1992-10-08 1995-07-21 Ciba Geigy
JP3598168B2 (ja) 1996-03-18 2004-12-08 独立行政法人 科学技術振興機構 抗ウイルス剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
JPH1165141A (ja) * 1997-08-11 1999-03-05 Canon Inc 電子写真感光体、該電子写真感光体を有するプロセスカ−トリッジ及び電子写真装置
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
JP2003525862A (ja) 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
DK2266537T3 (en) 1999-04-01 2014-12-15 Talon Therapeutics Inc Compositions for treating cancer
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
CA2386793C (en) * 1999-08-02 2006-03-28 F. Hoffmann-La Roche Ag New selective retinoid agonists
JP2001097860A (ja) 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
KR20010100194A (ko) 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
AU2002307217A1 (en) 2001-03-28 2002-10-15 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
AU2002357012A1 (en) 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
KR20040096497A (ko) 2001-11-29 2004-11-16 테라코스, 인크. 체외 광분리반출법 및/또는 세포소멸성 세포를 사용한특정 대상체의 전처리 방법
EP1487436A4 (en) * 2002-03-08 2009-06-03 Signal Pharm Inc POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
DK1344533T3 (da) * 2002-03-15 2007-01-08 Natimmune As Farmaceutiske præparater, der omfatter mannosebindende lectin
WO2004024145A1 (en) 2002-09-10 2004-03-25 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
WO2004026253A2 (en) * 2002-09-17 2004-04-01 Arqule, Inc. Novel lapacho compounds and methods of use thereof
TWI323662B (en) 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
IS6633A (is) 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
WO2005023824A2 (en) 2003-08-13 2005-03-17 University Of South Florida Methods for inhibiting tumor cell proliferation
US20050049207A1 (en) * 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
EP1706133B1 (en) 2003-12-02 2010-10-06 Cleveland Clinic Foundation Methods of protecting against radiation using flagellin
ES2385831T3 (es) * 2003-12-11 2012-08-01 Board Of Regents, The University Of Texas System Compuestos para el tratamiento de enfermedades celulares proliferativas
DE10359828A1 (de) 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
EP1748772A2 (en) * 2004-04-09 2007-02-07 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) * 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
CN101010316A (zh) * 2004-07-02 2007-08-01 艾科斯有限公司 用于抑制chk1的化合物
CN101023086A (zh) * 2004-08-18 2007-08-22 阿斯利康(瑞典)有限公司 选择性稠合的杂环及其应用
AU2005304952B2 (en) * 2004-11-08 2013-04-04 Baxter Healthcare S.A. Nanoparticulate compositions of tubulin inhibitors
BRPI0517887A (pt) * 2004-11-24 2008-10-21 Novartis Ag combinações de inibidores de jaks
WO2006071812A2 (en) * 2004-12-23 2006-07-06 H. Lee Moffitt Cancer Center And Research Institute Platinum iv complex inhibitor
CN101511179A (zh) * 2005-02-25 2009-08-19 密执安州立大学董事会 Stat3的小分子抑制剂及其用途
JP2006248978A (ja) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006290871A (ja) * 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
JPWO2006126505A1 (ja) 2005-05-26 2008-12-25 国立大学法人 東京大学 Ｓｔａｔ機能阻害剤およびその応用
WO2007013946A2 (en) * 2005-07-20 2007-02-01 University Of South Florida Method of predicting responsiveness to chemotherapy and selecting treatments
AU2006300877A1 (en) 2005-10-13 2007-04-19 Orchid Research Laboratories Limited Heterocyclic compounds as pSTAT3/IL-6 inhibitors
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
JP2007145680A (ja) 2005-11-30 2007-06-14 Idemitsu Kosan Co Ltd 水素発生材料および水素発生方法
EP1971578A1 (en) * 2005-12-24 2008-09-24 Biotica Technology Limited 21-deoxymacbecin analogues useful as antitumor agents
CA2635209A1 (en) * 2006-01-12 2007-08-02 Merck & Co., Inc. Fluorinated arylamide derivatives
WO2007092620A2 (en) * 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US20070243192A1 (en) * 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
CA2643562A1 (en) * 2006-02-24 2007-08-30 Anh Chau 2-(phenyl or heterocyclic)-1h-phenanthro[9,10-d]imidazoles
PL2514742T3 (pl) * 2006-03-31 2015-07-31 Univ Texas Leki przeciwnowotworowe będące pochodnymi kwasu kawowego dostępnymi biologicznie po podaniu doustnym
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US8828451B2 (en) * 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
WO2008077062A2 (en) * 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Suppression of stat3 reactivation after src kinase inhibition to treat cancer
JP4077863B1 (ja) * 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性２−（１−ヒドロキシエチル）−５−ヒドロキシナフト［２，３−ｂ］フラン−４，９−ジオンの製法
CA2736563C (en) 2007-09-10 2016-01-26 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2009060282A2 (en) 2007-11-06 2009-05-14 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
EP3108750B1 (en) 2010-03-19 2018-07-04 1Globe Biomedical Co., Ltd. Novel compounds and compositions for targeting cancer stem cells
MX394137B (es) 2010-03-19 2025-03-24 Boston Biomedical Inc Compuestos y composiciones novedosas para atacar las células madre del cáncer.
AU2015218436B9 (en) 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
LT2547205T (lt) 2010-03-19 2024-06-10 1Globe Biomedical Co., Ltd. Nauji tikslinio poveikio vėžio kamieninėms ląstelėms būdai
CN103402993A (zh) 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
MX2015014181A (es) 2013-04-09 2016-05-24 Boston Biomedical Inc 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
MX2017013358A (es) 2015-04-17 2018-08-01 Boston Biomedical Inc Métodos para tratar el cáncer.
BR112017022281A2 (pt) 2015-04-17 2018-07-10 Boston Biomedical Inc métodos para tratar câncer
TW201713328A (zh) 2015-04-17 2017-04-16 波士頓生醫公司 治療癌症之方法
BR112017022958A2 (pt) 2015-04-27 2018-07-17 Boston Biomedical Inc métodos para tratamento de câncer com inibidor da via da stat3 e inibidor de quinase
WO2016196935A1 (en) 2015-06-03 2016-12-08 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
WO2017132049A1 (en) 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
US10646464B2 (en) 2017-05-17 2020-05-12 Boston Biomedical, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
EP3067054A1 (en) 2016-09-14
CY1118476T1 (el) 2017-07-12
CN104586832B (zh) 2018-02-16
JP2010539097A (ja) 2010-12-16
PL2200431T3 (pl) 2017-01-31
JP2018076349A (ja) 2018-05-17
CA2911990C (en) 2018-03-20
WO2009036101A1 (en) 2009-03-19
EP2200431B1 (en) 2016-07-20
WO2009036059A3 (en) 2009-07-02
JP2016034976A (ja) 2016-03-17
EP2194987A2 (en) 2010-06-16
JP2015034179A (ja) 2015-02-19
JP2020143135A (ja) 2020-09-10
US9732055B2 (en) 2017-08-15
JP2015038151A (ja) 2015-02-26
DK2190429T3 (en) 2016-05-30
PL3067054T3 (pl) 2021-10-04
CN105963289A (zh) 2016-09-28
JP6346628B2 (ja) 2018-06-20
CA2911990A1 (en) 2009-03-19
SI2200431T1 (sl) 2016-10-28
EP3058941B1 (en) 2019-05-22
US20170197932A1 (en) 2017-07-13
US8877803B2 (en) 2014-11-04
US10851075B2 (en) 2020-12-01
US10377731B2 (en) 2019-08-13
JP2010539098A (ja) 2010-12-16
CN101854802A (zh) 2010-10-06
HK1148943A1 (en) 2011-09-23
PL2194987T3 (pl) 2017-01-31
ES2583010T3 (es) 2016-09-16
PT2194987T (pt) 2016-08-05
EP2194987A4 (en) 2011-11-30
US20210115006A1 (en) 2021-04-22
CA2736532C (en) 2018-03-20
JP5688840B2 (ja) 2015-03-25
CN103288787A (zh) 2013-09-11
CY1117604T1 (el) 2017-04-26
HK1148942A1 (zh) 2011-09-23
CN101854937A (zh) 2010-10-06
EP2190429A4 (en) 2011-12-14
US20200039948A1 (en) 2020-02-06
US20180030022A1 (en) 2018-02-01
DK2194987T3 (en) 2016-08-15
US20190135773A1 (en) 2019-05-09
EP2200431A1 (en) 2010-06-30
EP2194987B1 (en) 2016-05-18
DK2200431T3 (en) 2016-08-15
JP2019073560A (ja) 2019-05-16
EP2190429A1 (en) 2010-06-02
CY1117833T1 (el) 2017-05-17
CN103288787B (zh) 2016-08-03
US9745278B2 (en) 2017-08-29
CA2736563A1 (en) 2009-03-19
CN101854930A (zh) 2010-10-06
US20190263768A1 (en) 2019-08-29
PL2190429T3 (pl) 2016-09-30
JP5872160B2 (ja) 2016-03-01
JP6106149B2 (ja) 2017-03-29
JP2016065101A (ja) 2016-04-28
JP2016147906A (ja) 2016-08-18
EP2190429B1 (en) 2016-04-20
EP3050566A3 (en) 2016-11-30
US20110112180A1 (en) 2011-05-12
JP2016094465A (ja) 2016-05-26
WO2009036059A2 (en) 2009-03-19
US20180030021A1 (en) 2018-02-01
JP2018131464A (ja) 2018-08-23
WO2009036099A1 (en) 2009-03-19
JP6347795B2 (ja) 2018-06-27
CA2736532A1 (en) 2009-03-19
SI2194987T1 (sl) 2016-10-28
PT2200431T (pt) 2016-08-03
CN101854937B (zh) 2013-03-27
US9834532B2 (en) 2017-12-05
HRP20160430T1 (hr) 2016-05-20
JP5701603B2 (ja) 2015-04-15
ES2584904T3 (es) 2016-09-30
JP2014231522A (ja) 2014-12-11
EP2200431A4 (en) 2011-12-21
EP3067054B1 (en) 2020-12-30
JP2010539095A (ja) 2010-12-16
US20150018410A1 (en) 2015-01-15
HUE027657T2 (en) 2016-11-28
JP2020117547A (ja) 2020-08-06
US20100310503A1 (en) 2010-12-09
SI2190429T1 (sl) 2016-10-28
CN104586832A (zh) 2015-05-06
CN105963289B (zh) 2021-02-26
EP3050566A2 (en) 2016-08-03
US20120252763A1 (en) 2012-10-04
ES2569215T3 (es) 2016-05-09
HK1148906A1 (en) 2011-09-23
EP3050566B1 (en) 2018-11-28
CN101854930B (zh) 2016-05-04
CA2736564A1 (en) 2009-03-19
CN101854802B (zh) 2014-12-03
JP2014221843A (ja) 2014-11-27
US20210024482A1 (en) 2021-01-28
DK3050566T3 (en) 2019-03-11
JP5938072B2 (ja) 2016-06-22
HUE027443T2 (en) 2016-10-28
HUE029111T2 (en) 2017-02-28
JP5925849B2 (ja) 2016-05-25
HRP20160625T1 (hr) 2016-08-12
EP3058941A1 (en) 2016-08-24
CA2736563C (en) 2016-01-26
JP6358659B2 (ja) 2018-07-18

Similar Documents

Publication Publication Date Title
HRP20160949T1 (hr) Novi sastavi i metode za liječenje karcinoma
SI2894165T1 (sl) Postopki in sestavki za zdravljenje motenj povezanih s komplementom
DK2195015T3 (da) Sammensætning til behandling af prostatacancer
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
LT2478907T (lt) Kompozicijos vėžiui gydyti
CR10667A (es) Compositions and methods for diagnosing and treating cancer
EP2120561A4 (en) COMPOSITIONS FOR TREATING BIOFILMS, AND METHODS FOR THEIR USE
BRPI0812562A2 (pt) composições terapêuticas anti-cd20 e métodos
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
HRP20190526T1 (hr) Postupak za obradu pucolana
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
DK2101805T3 (da) Integrinligander til anvendelse i behandling af cancer
BRPI0822349A2 (pt) composições e métodos para tratar doenças lisossômicas
EP2231185A4 (en) METHOD AND COMPOSITIONS FOR TREATING LIQUID TUMORS
IL210097A0 (en) Compositions and methods for treating unfluenza
PL2187967T3 (pl) Sposoby i kompozycje do leczenia raka
PL2205720T3 (pl) Kompozycja do leczenia stwardnienia rozsianego
HRP20170225T1 (hr) Fosfoplatini i njihova uporaba za liječenje karcinoma
BRPI0812932A2 (pt) Composições e métodos de tratar câncer
DK2147122T3 (da) Enzymatisk kræftbehandling
IL199881A0 (en) Compositions and methods for treating hematopietic malignancies
BRPI0810207A2 (pt) Métodos e composições para o tratamento de câncer
FI20075086A0 (fi) Aromikoostumus